Our data show that although NMYC is a well-established, clinical marker for tumor cell aggressiveness in neuroblastoma, NMYC is highly dependent on other factors in the heterogeneous presentation of neuroblastoma cells. This evidence concerns the gene MYCN and neuroblastoma.